<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941313</url>
  </required_header>
  <id_info>
    <org_study_id>3D229-CN-001</org_study_id>
    <nct_id>NCT04941313</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of 3D229 in Healthy Subjects</brief_title>
  <official_title>A Single-blind, Randomized, and Placebo-Controlled Phase 1 Study to Evaluate the Safety and Tolerability of 3D-229 by Intravenous Single Dose Escalation and Repeated Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3D Medicines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3D Medicines</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 Study to Evaluate the Safety and tolerability of 3D-229 in health subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-blind, Randomized, and Placebo-Controlled Phase 1 Study to Evaluate the Safety and&#xD;
      tolerability of 3D-229 by Intravenous Single Dose Escalation(SAD) and Repeated Doses(RD) in&#xD;
      Healthy Subjects. A SAD portion of the study consists of 2 sequential dose escalation&#xD;
      cohorts, whereas RD portion of the study consists of a single cohort receiving 4 weekly doses&#xD;
      of 3D229. In both SAD and RD study arms, subjects are randomized to receive either a study&#xD;
      intervention (3D229) or matching placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of 3D229-Adverse events</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Monitoring of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Serum concentration observed at end of a single dose and observed pre-dose during repeat doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Time to reach maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Terminal phase elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>The total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum GAS6</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>evaluate the serum GAS6 level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Single Dose Escalation-3D229</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Escalation- placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat Dose-3D229</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat Dose-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3D229</intervention_name>
    <description>3D229 is an investigational drug.</description>
    <arm_group_label>Repeat Dose-3D229</arm_group_label>
    <arm_group_label>Single Dose Escalation-3D229</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Repeat Dose-placebo</arm_group_label>
    <arm_group_label>Single Dose Escalation- placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects had no clinically significant condition or disease confirmed by&#xD;
             medical history, medical assessment, physical examination, clinical laboratory tests,&#xD;
             and 12-lead electrocardiogram (ECG) at screening and on the day prior to the first&#xD;
             study drug administration;&#xD;
&#xD;
          2. Male or female, aged 18-55 years at the time of signing the informed consent form;&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 30 kg/m 2 (Containing 18 and 30 kg/m 2 ) within&#xD;
             range;&#xD;
&#xD;
          4. Negative urine drug screen/alcohol breath test at screening and 1 day prior to first&#xD;
             study drug administration;&#xD;
&#xD;
          5. Has not used tobacco products (including nicotine patches/gum) within 3 months prior&#xD;
             to screening and agrees to avoid such products throughout the study;&#xD;
&#xD;
          6. Complete abstinence for at least 14 days prior to the first dose of study drug and&#xD;
             Take effective contraceptive measures within 3 months after the last dose(including&#xD;
             Complete abstinence、 barrier contraception and completed sterilization operation), no&#xD;
             fertility, sperm donation, egg donation program&#xD;
&#xD;
          7. If the subject is female, the serum pregnancy test at screening and urine pregnancy&#xD;
             test on the day before first dose should be negative;&#xD;
&#xD;
          8. Ability to fully read, understand and sign the informed consent form;&#xD;
&#xD;
          9. Ability to communicate adequately with the investigator and to comply with the&#xD;
             requirements of the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood pressure ≥ 140/90 mmHg or pulse &gt; 100 beats/min at rest at screening;&#xD;
&#xD;
          2. QT interval corrected for heart rate using Fridericia ' s formula (QTcF) &gt; 430 msec&#xD;
             (males) and &gt; 450 msec (females) at screening;&#xD;
&#xD;
          3. Pregnant or lactating women;&#xD;
&#xD;
          4. Males with partners in pregnancy;&#xD;
&#xD;
          5. Concurrently enrolled in another clinical trial, or received any study drug within 3&#xD;
             months prior to the first dose (or 5 drug half-lives, whichever is longer);&#xD;
&#xD;
          6. Subject has a history of drug or alcohol abuse or dependence within the past 1 year;&#xD;
&#xD;
          7. Use of any prescription or over-the-counter medications, including analgesics,&#xD;
             hormonal contraceptives (oral contraceptives or implanted contraceptives), natural&#xD;
             food supplements, or dietary/herbal supplements (including vitamins), 14 days or 5&#xD;
             drug half-lives, whichever is longer;&#xD;
&#xD;
          8. Donation of more than 200 mL of blood within 56 days prior to the first dose, or&#xD;
             planned to donate blood during the study until 1 month after completion of the study;&#xD;
&#xD;
          9. Hepatitis B virus (HBV) surface antigen, hepatitis C virus antibody (HCV), or human&#xD;
             immunodeficiency virus (HIV) test results are currently or ever positive;&#xD;
&#xD;
         10. Prior or current condition that, in the opinion of the investigator, may affect the&#xD;
             conduct of the study or observations (to be confirmed by medical history);&#xD;
&#xD;
         11. History or current patient ' s clinically significant disease,Including but not&#xD;
             limited to: active tuberculosis, asthma, angioedema, bronchospasm, ulcerative disease,&#xD;
             gastrointestinal hemorrhage, coagulation disorder, hypertension, edema, heart failure,&#xD;
             hypokalemia, hyperkalemia, cardiovascular disease, hypersensitivity to any biological&#xD;
             agent, and significant impact on immune responseSevere skin diseases or other&#xD;
             conditions of the force;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xueying ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hailan Qian</last_name>
    <phone>13916228245</phone>
    <email>hailan.qian@3d-medicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Hongkou District</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xueying ding, Dr.</last_name>
      <phone>13761642319</phone>
      <email>xueying.ding@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

